Top

Published in:

Open Access 01-02-2011 | Poster presentation

Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects

Authors: CF Nagy, M Lynn, J Gogate

Published in: Critical Care | Special Issue 1/2011

Excerpt

Eritoran tetrasodium (E), a TLR4 antagonist, is currently being evaluated in phase 3 as a treatment for severe sepsis and has been well tolerated in clinical trials [1]. The primary objective of this study was to evaluate the effect of E on QTc in healthy subjects. …

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis.[http://clinicaltrials.gov/ct2/show/NCT00334828?term=eritoran&rank=2]

Title: Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
Authors: CF Nagy
M Lynn
J Gogate
Publication date: 01-02-2011
Publisher: BioMed Central
Published in: Critical Care / Issue Special Issue 1/2011
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc9684

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Anemia profile in critical septic patients hospitalized in the ICU

Interactions of nebulized heparin with intravenous antithrombin for combined therapy of acute lung injury

Hypophosphatemia of prognostic value in acute exacerbation of COPD

Effects of tigecycline and doxycycline in porcine endotoxemia

Failure to define level 1 care

Impact of a program of training on the performance of a track and trigger system and outcome of ICU admissions